Evidence map›Paper›PMID 28579838›Full record

ArticleInternational medical case reports journal2017

Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report.

Elisabetta Gambale, Consiglia Carella, Paolo Amerio, Fiamma Buttitta, Rosa Lucia Patea, Clara Natoli, Michele De Tursi

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International medical case reports journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Elisabetta GambaleMedical Oncology Unit, Department of Medical, Oral and Biotechnological Sciences.
Consiglia CarellaMedical Oncology Unit, Department of Medical, Oral and Biotechnological Sciences.
Paolo AmerioDepartment of Dermatology and Venereology, University G. d'Annunzio, Chieti.
Fiamma ButtittaDepartment of Medicine and Aging Sciences, University of Chieti-Pescara, Chieti.
Rosa Lucia PateaDepartment of Radiologic Sciences, University of Chieti-Pescara, Chieti, Italy.
Clara NatoliMedical Oncology Unit, Department of Medical, Oral and Biotechnological Sciences.
Michele De TursiMedical Oncology Unit, Department of Medical, Oral and Biotechnological Sciences.
Department of Medical Sciences · RUUniversity of Chieti-Pescara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several small molecules, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib and afatinib, have been demonstrated to significantly improve clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but erlotinib activity in EGFR wild-type squamous carcinoma is still highly debated. Here, we describe a prolonged and unexpected clinical response to erlotinib in a male former heavy cigarette smoker with wild-type EGFR squamous-cell cancer.

Indexed as

EGFR wild typeerlotinibsquamous NSCLC

Identifiers

PMID28579838
PMCPMC5449169
OpenAlexW2619339565

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.